22 de octubre de 2019
24 de septiembre de 2009

Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects (1)


Eisai concentrates its R&D activities in three key areas:
- Integrative Neuroscience, including Alzheimer's disease,
neuropathic pain and epilepsy.
- Integrative Oncology, including anticancer therapies, tumor
regression, tumor suppression and antibodies; supportive cancer
therapies include nausea and vomiting.
- Vascular/Immunological Reaction including acute coronary
syndrome, atherothrombotic disease and sepsis.

(1) Morphotek, Inc. and Eisai Corporation of North America ESMO abstract. "Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: preliminary data from a phase-2 study."

[TAB]

A. Pg. 1, col. 1, par. 1

B. Pg. 1, col. 1., par 3

[FTAB]

(CONTINUA)